Organogenesis said today that it acquired NuTech Medical for an undisclosed price. The combined company plans to feature a portfolio of wound care products and surgical biologics.
Birmingham, Alabama-based NuTech Medical will keep it’s non-biologics product line as a separate company called NuTech Spine.
“This is an important transaction for the regenerative medicine field. It unites 2 pioneering companies, each with decades of experience in bringing quality biologics products to patients around the world,” Organogenesis president & CEO Gary Gillheeney, Sr., said in prepared remarks. “This is a compelling, highly complementary combination of best-in-class, innovative products in both the regenerative wound and surgical biologics markets. Organogenesis is currently growing at 40% a year, and we have patiently waited to enter the amniotic tissue space. Specifically, we’ve been watching the development of next-generation amniotic products, and we’ve found in NuTech Medical what we believe is the field’s most promising product portfolio and pipeline, with a technology platform that’s really unparalleled in the field.”
NuTech’s president & CEO, Howard Walthall, will join Organogenesis as president of the company’s surgical division and senior VP for strategy and development.
“This is an exciting time for NuTech Medical, as we share with Organogenesis a commitment to regenerative product innovation, and a culture of scientific advancement and exceptional customer service,” Walthall added. “Like NuTech, Organogenesis has decades of experience bringing ground-breaking technology to market, and building a large and loyal customer base. This acquisition enables us to drive significant growth in both the wound and surgical biologics markets together, through our combined R&D programs, and our strong and proven distribution networks.”
NuTech has developed amniotic allografts for soft tissue and bone applications, including Affinity, NuShield, NuCel and ReNu.
Yesterday, Organogenesis launched its PuraPly Antimicrobial clinical research program, which will evaluate patients treated with PuraPly AM for up to 12 weeks. The 1st studies have started enrolling patients, according to Organogenesis.
The Canton, Mass.-based company’s PuraPly AM is a 510(k)-cleared device indicated for the management of acute and chronic wounds. The device is made of a bi-layered purified Type I collagen sheet, loaded with a broad spectrum antimicrobial agent that acts as a barrier against microbial colonization within wound dressings.
The NY-based studies will evaluate the device as an antimicrobial wound management therapy, as well as its ability to manage bioburden, support granulation tissue formation and support wound closure, Organogenesis reported.
